View Press Releases
Microbiosci Releases LPS Extraction Service to Support Managing Endotoxins Issues
Microbiosci, the mature branch of Creative Biogene, is designed especially for accelerating the development of the microbial industry. With unique technologies and satisfactory services in microbial genome editing, identification, sequencing, proteomics and metabolomics, Microbiosci is gradually becoming a leading custom service provider in delivering medicine microbiology solutions to clinical, pharmaceutical and veterinary. Recently, Microbiosci announced the release of its LPS extraction service to support managing endotoxins issues.
Microbiosci provides LPS isolation, purification, detailed chemical characterization, quantification and removal services to help companies including the vaccine industry, in vitro diagnostics, cosmetics and medical devices manage endotoxin problems. Lipopolysaccharide (LPS) as an antigen and adjuvant has been widely used in vaccine technology, allergen immunotherapy, treatment of immune-related diseases/disorders, LPS-related inflammatory processes and sepsis. Microbiosci uses an innovative proprietary protocol to extract high-purity and functionally active lipopolysaccharides (LPS) from different gram-negative bacteria with different LPS structures.
Microbiosci offers LPS production methods for lipopolysaccharide (LPS) separation and purification that are relatively more efficient (increased yield), clean (from 95% pure to 99% ultrapure), safe (non-toxic solvents) and cost-effective LPS extraction, and has the potential to scale up. In conclusion, Microbiosci's LPS extraction service is suitable for a variety of Gram-negative bacteria and provides customers with detailed experimental data and reports.
In addition, Microbiosci has established a complete LPS characterization platform, including a mass spectrometry technology platform, to provide detection service assistance according to customer needs. Removal of bacterial endotoxins from therapeutic biomolecules including proteins, peptides, nucleic acids, and vaccines is a challenging and expensive process and an important goal in the pharmaceutical industry and clinical practice. As an expert in the field of microbiology, Microbiosci has been focusing on LPS research, especially related to endotoxin removal in therapeutic products.
Creative Biogene focuses on the research, development and commercialization of microbial-related products and customized services. Microbiosci's proprietary endotoxin extraction method enables rapid, ultra-pure production of LPS from any species of Gram-negative bacteria at room temperature, with no toxic residues.
“We provide one-stop microbial fermentation services based on your specific application and commercial needs.” said Marcia Brady, the marketing director of Creative Biogene, she also added, “We have extensive experience in microbial fermentation and problem-solving capabilities which enable our team to provide comprehensive microbial manufacturing services.”
Microbiosci, as the division of Creative Biogene, is always dedicated to satisfying the needs of clients covering more than 50 countries and districts. As a leading custom service provider in delivering medicine microbiology solutions, Microbiosci has become a well-recognized industry leader with years of experience and professional scientists.